Payment overview · 2025
General Payments
$22,817.26
173 reported records · 17 companies
Healthcare provider profile · identity verified
Doojin Kim, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SANTA MONICA, CA · NPI 1487679858
Verified facts
What the public records show
CMS Open Payments records show Doojin Kim, MD received $22,817.26 in general payments during 2025 across 173 reported records.
TG Therapeutics, Inc. accounted for 83.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18,952.10 | 83.1% | 27 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $714.74 | 3.1% | 27 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $691.48 | 3.0% | 34 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $484.75 | 2.1% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $368.71 | 1.6% | 29 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $359.05 | 1.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $246.96 | 1.1% | 12 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $223.79 | 1.0% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $154.10 | 0.7% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $136.00 | 0.6% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $123.39 | 0.5% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $122.34 | 0.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $72.58 | 0.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $70.79 | 0.3% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.58 | 0.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.02 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.88 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,485.00 | 6 |
| Food and Beverage | $4,522.97 | 160 |
| Travel and Lodging | $1,697.80 | 6 |
| Education | $111.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $18,952.10 | 27 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $576.31 | 26 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $504.99 | 25 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $484.75 | 14 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $368.71 | 29 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $367.66 | 17 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $323.82 | 17 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $296.47 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $238.38 | 11 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $170.27 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $154.10 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $138.43 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $123.39 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $70.79 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $67.19 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $50.58 | 2 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.69 | 3 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.51 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $8.58 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $8.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 131 | 33 |
| Levetiracetam | Levetiracetam | 113 | 28 |
| Gabapentin | Gabapentin | 90 | 29 |
| Donepezil Hcl | Donepezil Hcl | 74 | 20 |
| Primidone | Primidone | 59 | 20 |
| Topiramate | Topiramate | 55 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Memantine Hcl | Memantine Hcl | 50 | 13 |
| Pregabalin | Pregabalin | 48 | 14 |
| Aimovig Autoinjector | Erenumab-Aooe | 46 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 46 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 26 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Modafinil | Modafinil | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Levetiracetam Er | Levetiracetam | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,817.26 · 173 records | TG Therapeutics, Inc. | AUSTEDO XR, Andembry, BOTOX, BRIUMVI, CREXONT, EMGALITY, Hizentra, INGREZZA, KESIMPTA, Kcentra, LEQEMBI, Mavenclad, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, QULIPTA, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYEPTI, WATCHMAN FLX, ZAVZPRET, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error